Trevi Therapeutics, Inc. - Common Stock (TRVI)

This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.

Trevi Therapeutics (NASDAQ:TRVI) outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent fi

This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.

Trevi Therapeutics (TRVI) Earnings Transcript

The company announced its decision following a meeting with the U.S. Food and Drug Administration.

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Trevi Therapeutics reported a narrower-than-expected Q3 2025 loss. The biopharma firm is preparing its Phase 3 program for Haduvio and has cash into 2028.

Trevi's Haduvio met its primary endpoint in a Phase 2b trial for IPF-related chronic cough, with statistically significant results at multiple doses.

In today's session, these stocks are experiencing unusual volume.